The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2243-2250

  Taylor, Allen J ^a   Lee, Hyun J ^a   Sullenberger, Lance E ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Clinical trials; Lipids; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY INTIMA; ARTERY MEDIA; ATHEROSCLEROSIS; CAROTID ARTERY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA;

EID: 33751217682     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148508     Document Type: Conference Paper

References (36)

1. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-52
2. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-43
3. Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study. Circulation 2005;112:498-504
4. Tkac I, Mudrikova T, Szaboova E, et al. Carotid intima-media thickness in type 2 diabetes is more strongly related to serum apoprotein A-I in females. Wien Klin Wochenschr 2001;113:194-8
5. Despres JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000;153:263-72
6. Brewer HB, Jr., Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004;24:1755-60
7. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004;101:9774-9
8. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43
9. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104
10. Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005;294:2492-4
11. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
12. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-9
13. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445
14. O'Leary DH, Polak JF, Wolfson SKJ, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1991;22:1155-63
15. Smilde TJ, Wollersheim H, Van Langen H, et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci (Lond) 1997;93:317-24
16. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60
17. van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002;359:37-42
18. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41
19. von BC, Hartmann M, Mintz GS, et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004;110:1579-85
20. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
21. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
23. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
24. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
25. Linn S, Fulwood R, Rifkind B, et al. High density lipoprotein cholesterol levels among US adults by selected demographic and socioeconomic variables. The Second National Health and Nutrition Examination Survey 1976-1980. Am J Epidemiol 1989;129:281-94
26. Pfeffer MA, Sacks FM, Moye LA, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999;33:125-30
27. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
28. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts [published erratum appears in JAMA 1988 May 13;259:2698]. JAMA 1987;257:3233-40
29. Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005;25:2416-21
30. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
31. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet 2004;363:1892-4
32. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B [see comments]. N Engl J Med 1990;323:1289-98
33. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up [see comments]. JAMA 1990;264:3013-17
34. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-52
35. Junyent M, Cofan M, Nunez I, et al. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006;26:1107-13
36. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/ovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8